Work

Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients

Year: 2019

Type: article

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a common cause of chronic kidney disease (CKD) worldwide. It is also the most common genetic cause of CKD, resulting from mutations in the PKD1 and PKD2 genes.S1 The clinical course is characterized by progressive enlargement of renal cysts, often culminating in end-stage renal disease (ESRD).

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2019.08.010

Authors: Mark R. Hanudel, Isidro B. Salusky, Renata C. Pereira, Wei Wang, Zhiying You, Kristen L. Nowak, Godela M. Brosnahan, Vicente E. Torres, Arlene B. Chapman, Ronald D. Perrone, Theodore I. Steinman, Kyongtae T. Bae, Berenice Y. Gitomer, Michel B. Chonchol

Institutions: University of California, Los Angeles, University of Colorado Anschutz, Mayo Clinic, University of Chicago, Tufts University, Tufts Medical Center, Beth Israel Deaconess Medical Center, University of Pittsburgh

Language: English

Topic: Genetic and Kidney Cyst Diseases

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,625

Funders: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences

Awards: FGF-23 and clinical outcomes in ADPKD patients, Regulation of Fibroblast Growth Factor 23 by Iron and Anemia in Chronic Kidney Disease, Novel treatment for polycystic kidney disease, Harvard Clinical and Translational Science Center

OpenAlex ID: W2969827439

FWCI: 0.603

Cites: 9

Cited by: 7

Related to: 10